AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
Company profile
Ticker
AMAG
Exchange
Website
CEO
Scott D. Myers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADVANCED MAGNETICS INC, AMAG PHARMACEUTICALS INC.
SEC CIK
Corporate docs
Subsidiaries
AMAG Pharmaceuticals Canada Corporation • AMAG Europe Limited • AMAG Securities Corporation • AMAG Pharma USA, Inc. • Drugtech Sárl, a Swiss company • Lumara Health Services Ltd. • Perosphere Pharmaceuticals Inc. ...
IRS number
42742593
AMAG stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
27 Nov 20
POSASR
Automatic shelf registration (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
Transcripts
AMAG
Earnings call transcript
2020 Q2
9 Aug 20
AMAG
Earnings call transcript
2020 Q1
11 May 20
AMAG
Earnings call transcript
2019 Q4
4 Mar 20
AMAG
Earnings call transcript
2019 Q3
1 Nov 19
AMAG
Earnings call transcript
2019 Q2
7 Aug 19
AMAG
Earnings call transcript
2019 Q1
7 May 19
AMAG
Earnings call transcript
2018 Q4
7 Feb 19
AMAG
Earnings call transcript
2018 Q3
1 Nov 18
AMAG
Earnings call transcript
2018 Q2
4 Aug 18
AMAG
Earnings call transcript
2018 Q1
3 May 18
Latest ownership filings
SC 13G/A
Camber Capital Management LP
16 Feb 21
SC 13G/A
Palo Alto Investors LP
16 Feb 21
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
10 Feb 21
4
DAVEY SCOON
17 Nov 20
4
Anne M. Phillips
17 Nov 20
4
DAVID EDWARD JOHNSON
17 Nov 20
4
Change in insider ownership
17 Nov 20
4
Kelly Schick
17 Nov 20
4
JAMES R SULAT
17 Nov 20
4
Joseph Vittiglio
17 Nov 20
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 98.48 mm | 98.48 mm | 98.48 mm | 98.48 mm | 98.48 mm | 98.48 mm |
Cash burn (monthly) | 179.00 k | 4.37 mm | (no burn) | 4.03 mm | (no burn) | 1.34 mm |
Cash used (since last report) | 7.68 mm | 187.53 mm | n/a | 172.87 mm | n/a | 57.33 mm |
Cash remaining | 90.80 mm | -89.05 mm | n/a | -74.39 mm | n/a | 41.15 mm |
Runway (months of cash) | 507.3 | -20.4 | n/a | -18.5 | n/a | 30.8 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|